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Introduction: Lysosomal storage disorders (LSD) are often characterized by abnormal
brain development, reflected by a reduction of intracranial volume (ICV). The aim of our
study was to perform a volumetric analysis of intracranial tissues in Fabry Disease (FD),
investigating possible reductions of ICV as a potential expression of abnormal brain
development in this condition.
Materials andMethods: Forty-two FD patients (15males, mean age 43.3± 13.0 years)
were enrolled along with 38 healthy controls (HC) of comparable age and sex. Volumetric
MRI data were segmented using SPM12 to obtain intracranial tissue volumes, fromwhich
ICV values were derived.
Results: Mean ICV of FD patients was 8.1% smaller compared to the control group
(p< 5·10−5). Unlike what typically happens in neurodegenerative disorders, no significant
differences emerged when comparing between the two groups the fractional volumes of
gray matter, white matter and CSF (i.e., normalized by ICV), consistent with a harmonious
volumetric reduction of intracranial structures.
Discussion: The present results suggest that in FD patients an abnormality of brain
development is present, expanding the current knowledge about central nervous system
involvement in FD, further emphasizing the importance of an early diagnosis.
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INTRODUCTION
Fabry disease (FD) is a rare, X-linked disorder characterized by a progressive accumulation of
globotriaosylceramide (Gb3) and related glycosphingolipids in different cells (1, 2). In contrast
to many other lysosomal storage disorders (LSD) (3, 4), FD is regarded as a clinical adult-onset
condition, withmost patients remaining asymptomatic in the first years of life and thenmanifesting
the characteristic multisystemic signs of the disease (2).
The use of advanced MRI techniques has recently suggested that different mechanisms of brain
damage could be present in FD, with the vision of this disorder slowly changing from a purely
cerebrovascular disease to a condition characterized by a more global and multifaceted cerebral
involvement (5–9).
Pontillo et al. Reduced Intracranial Volume in Fabry Disease
Of note, the physiopathology of CNS alterations in FD has
not yet been completely understood. Along with vascular and
neurodegenerative mechanisms, both due to glycosphingolipid
accumulation, the possibility that in FD, similarly to other LSD,
an abnormal development of CNS could occur has never been
fully investigated.
Indeed, although several studies were conducted to investigate
possible changes in relative brain tissue (especially gray matter –
GM–) volumes in FD (7, 8, 10), to the best of our knowledge, no
study has focused on the evaluation of total intracranial volume
(ICV). This latter measure represents a proxy for the maximal
brain growth obtained during development and maturation
(11, 12), whose changes may represent a possible indicator of
neurodevelopmental anomaly.
With this knowledge, aim of our study was to perform a
volumetric analysis of intracranial tissues in FD, investigating
possible differences in terms of ICV between FD patients and
a group of healthy controls (HC) as a possible expression of
abnormal brain development in this condition.
MATERIALS AND METHODS
Participants
Brain MRI studies of 42 patients with genetically proven FD,
no history of any cerebrovascular events and classical phenotype
of the disease were analyzed, along with those from 38 HC
of comparable age and sex. For both groups exclusion criteria
included a history of neurologic or major psychiatric disorders
and systemic diseases that may affect the CNS (e.g., uncontrolled
endocrine disorder), as well as the presence of any significant
cerebral focal lesion on brain MRI.
Demographic and clinical information of all the subjects
included in the analysis are listed in Table 1, while genetic
findings are reported in Table s1 of the Supplementary Materials.
Standard Protocol Approvals,
Registrations, and Patient Consents
All participants gave informed written consent for use of their
images for research purposes. The study was approved by the
local institutional review board “Carlo Romano,” in accordance
to the Declaration of Helsinki.
MRI Data Acquisition
All MRI exams have been carried out on the same 3 Tesla MR
scanner (Trio, Siemens Medical Systems, Erlangen, Germany).
The sequences used for this study included a FLAIR sequence
for assessment of White Matter Hyperintensities (WMH) and an
isotropic T1w acquisition for the volumetric analysis, acquired
during the same scan session. Details of the acquired sequences
are reported in the Supplementary Materials.
Abbreviations: LSD, Lysosomal Storage Disorder; ICV, Intracranial Volume; FD,
Fabry Disease; HC, Healthy Control; WMH, White Matter Hyperintensities; fGM,
fractional Gray Matter; fWM, fractional White Matter; fCSF, fractional Cerebro-
Spinal Fluid; ERT, Enzyme-Replacement Therapy.
TABLE 1 | Participants’ demographic and clinical variables.
HC FD
Age (mean ± SD) 43.2 ± 14.5 43.3 ± 13.0
Sex (F–M) 23–15 27–15
ERT n/a 31/42
ERT duration (mean ± SD) n/a 51.8 ± 53.4
Hypertension n/a 11/42
Arrhythmia n/a 2/42
Left ventricular hypertrophy n/a 31/42
Renal failure n/a 14/42
Proteinuria n/a 22/42
Neuropathy n/a 30/42
Acroparesthesia n/a 29/42
Gastrointestinal involvement n/a 12/42
Cornea verticillata n/a 33/42
Angiocheratoma n/a 36/42
ERT, enzyme replacement therapy; FD, Fabry disease; HC, healthy control; n/a, not
applicable. Ages are expressed in years, while ERT duration is expressed in months.
Renal failure considered present when the estimated glomerular filtration rate of the patient
was <90 mL/min, while proteinuria was considered present when the patient scored a
value >150 mg/24 h.
MRI Data Analysis
Brain MR scans were visually assessed for the presence of
WMH by two neuroradiologists in consensus, blind to diagnosis.
The load of WMH was rated in all subjects, by grading
it separately in periventricular and deep hemispheric white
matter (WM), with a score ranging from 0 to 3 for each
location. The overall score (hereinafter Fazekas’ score) was
then calculated as the sum of the two values, as proposed
by Fazekas et al. within a recent multicenter MR study
on FD (13).
Analysis of structural T1-weighted MRI data was conducted
using the Statistical Parametric Mapping (SPM12) software
package (http://www.fil.ion.ucl.ac.uk/spm).
For ICV and global GM, WM, and cerebrospinal
fluid (CSF) volume measures, structural data were
processed using the unified segmentation tool (14);
and ICV was then computed with the “tissue volumes”
utility, by adding up the segmented GM, WM and CSF
volumes (15).
In addition, to investigate possible changes of intracranial
tissue volumes independent from ICV, fractional volumes of
brain tissues were calculated as their ratio to ICV, thus obtaining
fractional GM (fGM), fractional WM (fWM), and fractional CSF
(fCSF) (16, 17).
Finally, to investigate possible regional GM differences
between the two groups, a voxel based morphometry (VBM)
analysis was carried out. With this aim, the Diffeomorphic
Anatomical Registration Through Exponentiated Lie
Algebra (DARTEL) algorithm (18) was employed to
create a study-specific template for spatial normalization
of the segmented images. The resulting flow fields
created by the DARTEL procedure were then used to
generate spatially normalized, Jacobian scaled, resliced
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(2.0-mm isotropic voxels) and smoothed (8-mm FWHM
isotropic Gaussian kernel) GM maps in the standard MNI
space (19).
Statistical Analysis
Differences between FD and HC groups in terms of age and
sex were probed by Student t-test and by Chi-squared test,
respectively, while differences in terms of Fazekas’ score were
assessed using a Mann-Whitney test. A general linear model
(GLM), including age and sex as confounding covariates, was
employed to probe possible differences in terms of ICV and
fractional intracranial tissue volumes. Finally, correlations of
volumes with Fazekas’ score and clinical variables, including
cardiac and renal functions, as well as ERT duration, were
assessed by partial correlation analysis, correcting for age and
sex. These analyses were carried out using Statistical Package
for Social Science (SPSS) package (SPSS Inc., version 17.0,
Chicago, IL), with a two-tailed significance level of p < 0.05,
Bonferroni-corrected.
For the VBM analysis, differences between the two groups and
correlations with the Fazekas’ score and clinical variables were
also assessed by means of the GLM in SPM12, including in the
model age and sex, as well as ICV, to assess local differences
independent from head size. In comparing the two groups, both
contrasts (HC> FD and HC < FD) were probed, and differences
were considered significant for p< 0.05, corrected for the family-
wise error at cluster level.
RESULTS
The FD and HC groups were not significantly different for age
(43.3 ± 13.0 for FD vs. 43.2 ± 14.5 for HC; p = 0.96), and sex
(M–F= 27–15 vs. 23–15 for FD and HC, respectively; p= 0.73).
Among the FD patients, 20 out of 42 (47.6%) showed absence
of WMH in any regions, 17 patients had a Fazekas’ score of 1,
4 patients (9.5%) a score between 2 and 3, and only one patient
(2.4%) a high WMH load, scoring a total Fazekas’ score of 6. On
the other hand, 65.8% of controls (25 out of 38 subjects) showed
absence of significant WMH in any region (Fazekas’ score = 0),
12 (31.6%) had a Fazekas’ score of 1 and only one HC (3.1%) had
a Fazekas’ score of 2 (p= 0.07 at Mann-Whitney test).
When evaluating possible differences in terms of ICV, FD
patients showed significantly smaller volumes compared to HC,
with a mean ICV that was 8.1% lower compared to the control
group (1267.8 ± 121.5ml vs. 1379.8 ± 137.2ml in FD and
HC, respectively; p < 5·10−5; 95% confidence interval of the
difference= −149.1/−61.4ml) (Figure 1).
No significant differences emerged between the two groups
when comparing the fGM (50.5 ± 3.6% vs. 50.1 ± 3.9% in FD
and HC, respectively; p = 0.41; 95% confidence interval of the
difference=−0.6%/1.4%), the fWM (30.6± 2.0% vs. 31.4± 2.0%
in FD and HC, respectively; p = 0.10; 95% confidence interval of
the difference=−1.6%/0.1%) and the fCSF (18.8± 4.4% vs. 18.5
± 4.0% in FD and HC, respectively; p = 0.86; 95% confidence
interval of the difference = −1.0%/1.7%). The VBM analysis
revealed only a cluster of reduced GM density in FD patients
compared to HC at the level of the thalami, bilaterally, extending
FIGURE 1 | Box and whiskers plot showing the distribution of intracranial
volumes (ICV) for the Fabry disease (FD) and healthy controls (HC) groups. ICV
values are expressed in ml.
toward the left hippocampus (p= 0.001) (Figure 2; Table s2). No
significant clusters of increased GM density were found in FD
patients compared to HC.
Finally, when testing the relationship with WMH load and
clinical variables, no significant correlation emerged for ICV,
fractional intracranial tissue volumes or regional GM density.
DISCUSSION
We investigated volumetric alterations of intracranial structures
in FD patients, demonstrating a smaller ICV in these subjects
compared with HC, along with a preservation of fractional
intracranial tissue volumes. These results, taken together,
demonstrate a harmonious reduction of all intracranial tissue
volumes, supporting the hypothesis of a possible abnormality of
neural development in these patients.
ICV is defined as the sum of GM, WM, and CSF, and it is
a representation of the maximal brain growth obtained during
development and maturation (11, 12). Indeed, the peak of the
ICV is reached early in life, such that, by the age of 6 years,
total brain volume is 90% of adult volume and reaches full adult
volume during adolescence (20, 21). Once ICV peaks and the
skull sutures are completely fused, there is no further change
in this measure, regardless of changes that may occur in brain
tissues (22), which when occurring must be compensated by
changes in the CSF compartment volume.
Most sphingolipidoses, and LSD in general, are characterized
by the relatively prominent involvement of CNS, ranging from
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FIGURE 2 | Clusters of gray matter loss in Fabry disease (FD) patients compared to healthy controls (HC). Results are displayed for p < 0.05 FWE-corrected at
cluster level, and superimposed for anatomical reference to multi-planar reconstruction of a single subject T1-weighted volume in the standard Montreal Neurological
Institute space (A) sagittal, (B) coronal, (C) axial. No region of increased gray matter volume was present in FD patients compared to HC.
early developmental delay and microcephaly to more subtle
neurodevelopmental deficits (23–26).
Interestingly, some studies demonstrated a smaller ICV
as an evidence of neurodevelopmental defect not only in
early-onset neurodevelopmental disorders but also in other
genetic conditions mainly characterized by an adult-onset
neurodegeneration, such as Wolfram Syndrome or even
prodromal Huntington’s Disease (27, 28). These findings suggest
that in these diseases subtle neurodevelopmental phenomena
may occur already in the preclinical phases (27, 28).
In our study, we found significantly smaller intracranial
volumes in FD patients, a finding that could shed further light
on the mechanisms of cerebral involvement in FD, suggesting
for the first time that in these patients a neurodevelopmental
abnormality may be also present. Indeed, since ICV, once
determined by maximal brain growth in childhood, does not
change over time, a smaller volume could reflect an incomplete
growth of the brain parenchyma, as expression of a global
abnormality in the process of brain development (27).
A possible explanation to this finding could be traced to
the pathogenic mechanisms typical of FD. Indeed, it may be
hypothesized that α-galactosidase A could play a role in the
normal development of the CNS and, similarly to what happens
in many other LSD (23, 24, 26), its deficiency could lead to
detectable, although mild, neurodevelopmental abnormalities.
This speculation, coupled to other evidences demonstrating
the possibility of an early detection of clinical and subclinical
manifestations in pediatric FD patients (29, 30), could further
indicate that FD, once considered as an adult-onset condition,
is indeed a more complex phenomenon that encompass all
ages, also regarding CNS involvement. The present findings thus
further stress the importance of a timely diagnosis, or even
of newborn screening, and the possible advantages of an early
initiation of the enzyme-replacement therapy (ERT) (31). With
respect to this speculation, it should also be noted that the
absence of a significant correlation with the ERT duration is
in line with our hypothesis. Indeed, all FD patients included
in the study started the ERT as adults, where this possible
neurodevelopmental abnormality could have already developed.
To test this hypothesis, however, longitudinal studies including
pediatric FD patients should be performed, to further elucidate
any possible relationship between ERT and ICV variations.
Along with the evaluation of ICV, we have investigated
if different intracranial tissues were affected to a different
extent in FD, showing no difference between FD and HC in
terms of fractional intracranial tissue volumes. This finding,
coupled to the abovementioned ICV reduction in these patients,
indicates the presence of a harmonious volumetric reduction
of all intracranial structures in FD patients, rather than a pure
neurodegenerative phenomenon. Indeed, neurodegeneration
usually affects GM or the entire brain parenchyma volume,
determining a reduction of the corresponding fractional volumes,
typically with a compensatory increase in CSF volume to
maintain total ICV unchanged.
Interestingly, in the post-hoc VBM analysis we found two
clusters of reduced GM density involving both thalami with
extension to the left hippocampus, in absence of significant
correlation between regional GM volume and WMH load. This
finding is apparently in conflict with previous volumetric studies,
which failed to prove significant regional alterations in GM
volumes of FD patients (8, 9). A possible explanation to this
discrepancy may lay in the segmentation method used in the
present work, coupled to the larger sample examined in this
work, which provides a slightly greater statistical power, that
allowed to detect these subtle differences. Indeed, our analysis
was conducted with a different software package (i.e., SPM12)
compared to the one used in previous works (e.g., SPM8),
which has proved to be one of the most accurate method
for intracranial volumes assessment (15, 32). Supporting this
speculation, an additional analysis performed on the same
subjects with SPM8 led to no significant differences at the VBM
analysis (data not shown).
Indeed, our VBM findings are also partially in line with
previous studies that demonstrated hippocampal atrophy in
FD patients as a possible surrogate consequence of a primitive
neuronal involvement, independent from brain vasculopathy
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(7, 10). Moreover, similar findings were also reported in
other sphingolipidoses such as Niemann-Pick disease, indicating
a preferential volume reduction of subcortical gray matter
structures in these conditions (33, 34). Slightly more prominent
thalamic and hippocampal atrophy, in the context of a
generalized harmonic reduction of the volumes of all intracranial
compartments, could be the expression of an additional
abnormal development of subcortical GM or, more probably,
of a specific vulnerability to neurodegeneration due to selective
neuronal Gb3 accumulation in these structures, which has been
reported in anatomopathological studies (7, 35–37). However,
longitudinal and neuropsychological studies are needed to
further elucidate the physiopathological mechanisms and the
clinical meaning of this finding.
It is known that in this condition height is reported to be
below the US 50th percentile in young male patients, while no
significant difference is described for female patients (29). This
evidence could lead to the interpretation of our finding as an
expression of a generalized harmonious growth defect, rather
than a selective neurodevelopmental abnormality. To test this
hypothesis however, we retrospectively retrieved anthropometric
measures for the FD group from clinical records, which were
not significantly different from the reported values of the
adult population of the same geographical area for both males
[median height: 170 cm (range: 158–188 cm) vs. 174 cm in the
healthy population; p = 0.18; 95% confidence interval of the
difference = −6.72/1.38] and females [median height: 160 cm
(range: 145–175 cm); vs. 161 cm in the healthy population,
p= 0.81; 95% confidence interval of the difference=−2.92/2.30]
(38). Furthermore, an ancillary partial correlation analysis
(corrected for age and sex) proved no significant correlations
between height and ICV values (r = 0.225, p = 0.169; 95%
confidence interval for r = −0.089/0.498) in our patients.
Although these observations further support our speculation
that a reduction of ICV values could be the expression of
a neurodevelopmental abnormality, we could not fully test
this hypothesis as anthropometric measures were not available
in the HC group, so that further studies are warranted to
confirm it.
In conclusion, we demonstrated that FD patients show a
highly significant reduction of the ICV compared to HC, while
fractional volumes of intracranial tissues are preserved in this
condition. Our results further expand the current knowledge
about CNS involvement in FD, suggesting that in these patients
an abnormality of brain development could be present, thus
emphasizing the importance of an early diagnosis of FD, and
possibly of an early ERT initiation.
Further studies are needed to understand if this feature of the
disease is part of the spectrum of more generalized growth defect
encountered in this pathology, or it represents an independent
phenomenon.
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